Advertisement
Telix Pharmaceuticals Lim... (TLX)
Company Description
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis.
Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy.
Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
| Country | AU |
| IPO Date | Nov 14, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA |
Advertisement
Contact Details
Address: 55 Flemington Road North Melbourne, VIC AU | |
| Website | https://telixpharma.com |
Stock Details
| Ticker Symbol | TLX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002007191 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, MD, Group Chief Executive Officer & Executive Director |
| Richard Valeix M.B.A. | Chief Executive Officer of Telix Therapeutics |
| Craig Ulrick | Chief Information Officer |
| Darren Patti Pharm.D. | Group Chief Operating Officer |
| Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer |
| Dr. Paul Schaffer | Chief Technology Officer |
| Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor |
| Dr. David N. Cade M.B.A., M.D., MBBS | Group Chief Medical Officer |
| Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist |
| Kyahn Williamson B.A. | Senior Vice President of Corporate Communications & Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | 6-K | Filing |
| Apr 17, 2025 | 6-K | Filing |
| Apr 17, 2025 | 6-K | Filing |
| Apr 08, 2025 | 6-K | Filing |
| Apr 04, 2025 | 6-K | Filing |
| Mar 21, 2025 | 6-K | Filing |
| Mar 18, 2025 | 6-K | Filing |
| Mar 12, 2025 | 6-K | Filing |
| Feb 27, 2025 | 6-K | Filing |
| Feb 26, 2025 | 6-K | Filing |